Please assess the completion status of the following clinical trial:

Trial Title: Ketamine for Relapse Prevention in Recurrent Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years old~* Hamilton Rating Scale for Depression, 24-item (HRSD-24) score of ≥21~* Voluntary admission for treatment of acute depressive episode~* Meet DSM-IV criteria for recurrent depressive disorder (RDD): ≥2 previous depressive episodes with at least 2-months(consecutive) subthreshold or no symptoms in between PLUS(to enrich the sample for those at high risk for relapse) must also have experienced ≥3 major depressive episodes(including index episode) within the previous 2 years~For the randomised pilot trial, RDD patients must have:~* received antidepressant treatment for the acute depressive episode(pharmacological, psychotherapeutic or multidisciplinary)~* ≥60% decrease from baseline HRSD-24 score and score ≤16~* Standardised Mini-Mental State Examination (sMMSE) score of ≥24~* able to provide informed consent~Exclusion Criteria:~* Current involuntary admission~* Medical condition rendering unfit for ketamine/midazolam~* Active suicidal intention~* Dementia~* History of Axis 1 diagnosis other than RDD~* Electroconvulsive therapy (ECT) for treatment of current depressive episode~* Alcohol/substance abuse in previous six months~* Pregnancy or inability to confirm use of adequate contraception during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Trial Interventions: participants will receive four two-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
- Midazolam (Type: ACTIVE_COMPARATOR): Trial Interventions: participants will receive four two-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.

Based on this trial design, predict the completion outcome and termination type (if applicable).